Payment overview · 2025
General Payments
$128.62
1 reported records · 1 companies
Healthcare provider profile · identity verified
Avinash Chandra Vyas, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OKLAHOMA CITY, OK · NPI 1902878739
Verified facts
What the public records show
CMS Open Payments records show Avinash Chandra Vyas, MD received $128.62 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $128.62 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $128.62 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $128.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 726 | 229 |
| Atorvastatin Calcium | Atorvastatin Calcium | 639 | 202 |
| Pantoprazole Sodium | Pantoprazole Sodium | 446 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 327 | 102 |
| Losartan Potassium | Losartan Potassium | 319 | 97 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 294 | 91 |
| Gabapentin | Gabapentin | 286 | 77 |
| Metformin Hcl | Metformin Hcl | 270 | 83 |
| Tamsulosin Hcl | Tamsulosin Hcl | 261 | 81 |
| Prednisone | Prednisone | 241 | 119 |
| Furosemide | Furosemide | 238 | 94 |
| Alprazolam | Alprazolam | 217 | 32 |
| Meloxicam | Meloxicam | 208 | 66 |
| Eliquis | Apixaban | 204 | 59 |
| Omeprazole | Omeprazole | 200 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 190 | 57 |
| Allopurinol | Allopurinol | 185 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 180 | 64 |
| Lisinopril | Lisinopril | 171 | 53 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 163 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 161 | 44 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 149 | 48 |
| Potassium Chloride | Potassium Chloride | 148 | 57 |
| Simvastatin | Simvastatin | 141 | 40 |
| Pregabalin | Pregabalin | 135 | 34 |
| Spironolactone | Spironolactone | 135 | 47 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 34 |
| Carvedilol | Carvedilol | 126 | 46 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 124 | 56 |
| Glimepiride | Glimepiride | 121 | 39 |
| Buspirone Hcl | Buspirone Hcl | 99 | 28 |
| Clonidine Hcl | Clonidine Hcl | 99 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 95 | 23 |
| Trazodone Hcl | Trazodone Hcl | 95 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 87 | 29 |
| Sutab | Sod Sulf/Pot Chloride/Mag Sulf | 85 | 81 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 71 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 80 | 33 |
| Methylprednisolone | Methylprednisolone | 80 | 62 |
| Ropinirole Hcl | Ropinirole Hcl | 80 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 79 | 20 |
| Montelukast Sodium | Montelukast Sodium | 79 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 16 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 69 | 16 |
| Ozempic | Semaglutide | 69 | 11 |
| Celecoxib | Celecoxib | 68 | 29 |
| Jardiance | Empagliflozin | 66 | 19 |
| Lorazepam | Lorazepam | 65 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 64 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 27 |
| Azithromycin | Azithromycin | 59 | 52 |
| Benazepril Hcl | Benazepril Hcl | 58 | 17 |
| Chlorthalidone | Chlorthalidone | 58 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 58 | 15 |
| Metformin Hcl Er | Metformin Hcl | 57 | 19 |
| Atenolol | Atenolol | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 54 | 29 |
| Januvia | Sitagliptin Phosphate | 53 | suppressed |
| Diazepam | Diazepam | 51 | suppressed |
| Levofloxacin | Levofloxacin | 51 | 45 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 16 |
| Cefuroxime | Cefuroxime Axetil | 49 | 46 |
| Humalog Kwikpen U-100 | Insulin Lispro | 49 | suppressed |
| Levetiracetam | Levetiracetam | 47 | 14 |
| Ondansetron Odt | Ondansetron | 47 | 21 |
| Nitroglycerin | Nitroglycerin | 46 | 26 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Famotidine | Famotidine | 44 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 13 |
| Cephalexin | Cephalexin | 41 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 41 | 29 |
| Temazepam | Temazepam | 41 | suppressed |
| Glipizide | Glipizide | 40 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | 11 |
| Xarelto | Rivaroxaban | 38 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | 14 |
| Nifedipine Er | Nifedipine | 37 | 13 |
| Sertraline Hcl | Sertraline Hcl | 37 | 13 |
| Digoxin | Digoxin | 35 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Topiramate | Topiramate | 35 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | suppressed |
| Linzess | Linaclotide | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 23 |
| Tradjenta | Linagliptin | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Finasteride | Finasteride | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 15 |
| Methotrexate | Methotrexate Sodium | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 28 | 15 |
| Glipizide Er | Glipizide | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 27 |
| Sod Sulf-Potass Sulf-Mag Sulf | Sodium, Potassium,mag Sulfates | 28 | 28 |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | 19 |
| Colchicine | Colchicine | 27 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 27 | 11 |
| Methocarbamol | Methocarbamol | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 13 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Creon | Lipase/Protease/Amylase | 19 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 19 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | suppressed |
| Clonazepam | Clonazepam | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 13 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dexamethasone | Dexamethasone | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $128.62 · 1 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error